MAP2K1 and colorectal carcinoma: Among 939 CRC cases tested at our laboratory for MAP2K1 mutations within clinical practice and clinical research, only 2 (0.2%) showed MEK1 gain of function variants (c.199G>A, p.Asp67Asn; c.169A>G, p.Lys57Glu), thus confirming the rarity of these specific genetic alterations in CRC.